A Double-Blind, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy of TAK-475 [lapaquistat] Alone or co-Administered With Atorvastatin in Subjects With Primary Dyslipidemia
Phase of Trial: Phase III
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Lapaquistat (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Adverse reactions; Registrational
- Sponsors Takeda Global Research and Development Center
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2009 Planned number of patients changed from 1800 to 2130.
- 11 Sep 2007 Status changed from in progress to completed.